clinical trial
Synchron Pauses Trials of Its Brain Implant Due to Performance Issues
After its latest device failed to perform, brain-computer interface startup Synchon halted clinical trials. The company says it will upgrade the implant's hardware and is at work on a new device. Synchron has paused clinical trials of its second-generation device after it failed to perform as expected in initial study participants, WIRED has learned. The Brooklyn-based startup, a competitor to Elon Musk's Neuralink, is also undergoing a restructuring, which includes eliminating jobs and scaling back its footprint in New York while building up a team in San Diego to support the development of an entirely new device. Synchron is one of several companies developing brain-computer interface technology meant to allow people to control digital devices by reading brain signals and translating those signals into output commands.
Trying Tourette's device was the best day of my life
Trying Tourette's device was the best day of my life Image caption, Katie (right) and her mum Julia travelled to Nottingham from Hertfordshire to try out the device, which would help calm Tourette's symptoms When Katie was just a child, her tics were so relentless they left her bedridden with a sore throat for two weeks. The now 15-year-old says living with Tourette's, external affected her ability to sleep, eat, and caused her to miss school. But a wrist device developed by researchers in Nottingham helped her calm down in an instant. Katie recalled trying it on for the first time, and said: It was absolutely life-changing. It was like the best day of my life.
Did the World Just Gain Hundreds of Millions of Alzheimer's Patients?
Did the World Just Gain Hundreds of Millions of Alzheimer's Patients? A new definition of Alzheimer's includes people without symptoms. Experts are fiercely divided over whether that makes sense--and whether the new drugs really help. Many have heralded a golden age of Alzheimer's research, excited by the promise of new amyloid-targeting antibodies. Yet a large meta-study of such antibodies concluded that they probably result in "little to no difference" in the decline of memory and of cognitive ability. This July, some ten thousand people descended on London for the Alzheimer's Association International Conference. Another three thousand of us joined virtually. I'm an anthropologist, accustomed to conferences where croissants at coffee breaks count as a luxury. This one opened with six trumpeters dressed as Buckingham Palace guards, followed by dancers who discoed, vogued, and high-kicked through the history of British pop. After the first day's sessions, participants dispersed to parties; at one, singers in sequins belted out covers while someone played an illuminated, transparent violin. One night, the London Eye was lit purple to honor the people in attendance. The mood matched the spectacle. Joanne Pike, the Alzheimer's Association's president and C.E.O., announced that recent advances had brought the campaign against the disease to a "pivotal moment." Maria Carrillo, its chief science officer, hailed a groundswell of progress. That optimism followed decades of disappointment. Between 1974 and 2020, the U.S. government spent roughly twenty billion dollars on Alzheimer's research without seeing the approval of a single treatment designed to act on the disease's underlying biology, let alone stop or reverse its course. Today, Alzheimer's afflicts roughly one in nine Americans over sixty-five and, along with related dementias, has been estimated to cost the economy about three-quarters of a trillion dollars a year. In surveys, it ranks with cancer as the disease people fear most. It typically starts by robbing patients of recent memories--conversations they just had, where they put important objects--before corroding the basic functions of adult independence, from paying bills to managing medications. Eventually, it leaves patients unable to speak, move, swallow, or recognize close relatives.
OpenAI Invests in Startup That Uses Brain Implants to Detect Cancer
It's the latest in a growing wave of bets that AI companies are making on brain data. OpenAI's venture capital arm as well as Peter Thiel's Founders Fund are investing in Coherence Neuro, a startup developing a brain implant to detect and treat cancer . The investments are part of a $45 million seed funding round for Coherence and reflect Big Tech's burgeoning interest in brain data . Coherence's CEO and cofounder Ben Woodington says there is "growing synergy" between the big AI labs and companies building devices to decode the brain, known as brain-computer interfaces . "The idea of capturing data to train better models and use it to optimize treatments is going to be super important," he says.
Measles Is Becoming So Common That Treatments May Soon Be Needed
As the US sees its highest number of measles cases in decades and vaccination rates fall, researchers are developing drugs to help those who contract the virus or who are particularly vulnerable. Up until recently, measles vaccination has been so effective that there's been little medical or financial incentive to develop treatments for the disease. But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection. It will likely be years, however, before these countermeasures are available, and it's even more uncertain if those who refuse vaccines would take such treatments. Fueled by large outbreaks in South Carolina and Utah, the US had already surpassed last year's 2,289 measles cases, and it's only July.
What Are Fish Oil Supplements Good For? Here's Your Crash Course
A large-scale clinical trial has shown that even long-term consumption of DHA--an omega-3 fatty acid found in abundance in oily fish--may not lead to improvements in cognitive function. Docosahexaenoic acid (DHA), an omega-3 fatty acid found in abundance in oily fish such as mackerel and sardines, is thought to improve cognitive function by supporting connections between brain cells. However, it has never been conclusively demonstrated that DHA taken as a dietary supplement actually reaches the brain or provides measurable benefits against dementia . Against this backdrop, a research team at the USC School of Medicine has published the results of a large, two-year clinical trial involving older adults at elevated risk of developing Alzheimer's disease . The study found that while high-dose DHA supplements do indeed reach the brain, they did not improve memory or cognitive function, nor did they slow brain atrophy.
On Response-Adaptive Targeting Strategies for Multi-Treatment Experiments
Yagouti, Redouane, Degenne, Rรฉmy, Kaufmann, Emilie
Response-adaptive randomization (RAR) in clinical trials aims to improve ethical and statistical efficiency by dynamically allocating patients to treatments based on observed outcomes. While RAR based on a target optimal allocation have been extensively studied for two-arms settings, their extension to multi-treatment experiments ($K \geq 2$) remains theoretically fragmented, with most existing methods focusing on specific algorithms or restricted target allocations. In this paper, we introduce a unified framework for response-adaptive targeting, the $ฮฑ$-Rebalancing Targeting Strategies ($ฮฑ$RTS), which generalize the ERADE two-armed strategy of Hu et al. [2009]. We prove that all designs in this family share fundamental asymptotic properties: strong consistency, asymptotic normality of allocation proportions and treatment effect estimators, and asymptotic efficiency. To address sparse target regimes (where some treatments are asymptotically eliminated), we further propose $ฮฑ$RTS with Forced Exploration, a variant that guarantees infinite sampling for all treatments while preserving the asymptotic guarantees. Extensive simulations illustrate the finite-sample behavior of $ฮฑ$RTS variants in a 3-armed context, highlighting in particular the critical role of forced exploration in sparse settings.
Women Business Leaders on How To Solve AI's Inclusivity Problem
Follow this author to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. When Julie Kim takes over as CEO of pharmaceutical giant Takeda in June, she says she will be proud to be known as the first woman and Korean American to ever lead the company. "If you would have asked me 20-30 years ago, I would have said, 'I want to be known as a good leader, or a good business woman, or a good strategist without those labels," she said.